Diclofenac Patches Market - Size, Outlook, and
Opportunity Analysis, 2018-2026
Diclofenac is nonsteroidal anti-inflammatory drug (NSAID), which works in reducing hormones
that cause inflammation and pain in the body. Non-steroidal anti-inflammatory drugs (NSAIDs)
are the most widely used therapeutic class of analgesic compounds, indicated to use in relieving
post extraction pain. Diclofenac sodium is a commonly prescribed NSAID, which exhibits anti-
inflammatory, analgesic and anti-pyretic activity. Diclofenac transdermal patches are used to get
temporary relief of minor aches and pains of the muscle and joints that are applied directly to
the area of pain. Transdermal diclofenac patches are found to be more effective as compared to
the diclofenac tablets, owing to its once-daily application and lesser frequency of systemic
adverse effects. Transdermal patches have been developed to offer innovative drug delivery
system for diclofenac, with reduced incidence of systemic adverse effects due to lower plasma
concentrations. Diclofenac patches are designed to treat pain associated with conditions such as
gout, migraine, rheumatoid arthritis, sprains of muscles and joints and in mild to moderate
fever in some cases.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1792
Diclofenac Patches Market Drivers
Diclofenac patches market is expected to witness significant growth over the forecast period,
owing to high prevalence of chronic pain disease. According to the American Academy of Pain
Medicine (AAPM), in 2011, around 1.8 billion people suffered from chronic pain. Moreover, the
National Institutes of Health (NIH) estimates that one in 10 people in the U.S. suffer from
chronic pain. According to a study published in the British Medical Journal in 2016, nearly
one-third to half of the population in the U.K. suffers from chronic pain. Moreover, according
to the NIH estimates published in 2015 by the American Pain Society (APS), around 50 million
people in the U.S. suffered from chronic pain. Moreover, rising prevalence of pain and
increasing prevalence of diseases such as cancer and others are driving the diclofenac patches
market growth. For instance, according to the National Cancer Institute, in 2018, around
1,735,350 new cases of cancer are expected to be diagnosed in the U.S. and 609,640 people are